Ginkgo Bioworks Raises $350M in Series E
Ginkgo Bioworks has successfully raised $350M in a Series E at a $4.9B valuation led by Baillie Gifford, ARK Investment Management.
Company Overview
Ginkgo Bioworks is a Biotech company headquartered in Boston, MA, founded in 2008 with 600+ employees.
Synthetic biology and organism engineering
Fundraising Details
- Amount Raised: $350M
- Round Type: Series E
- Valuation: $4.9B
- Date: 2020-09-15
- Investors: Baillie Gifford, ARK Investment Management
About Ginkgo Bioworks
Synthetic biology and organism engineering The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Boston, MA
- Founded: 2008
- Team Size: 600+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Ginkgo Bioworks's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Ginkgo Bioworks's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $4.9B valuation marks an important milestone for Ginkgo Bioworks, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Ginkgo Bioworks is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2020-09-15. For more information about Ginkgo Bioworks, visit their headquarters at Boston, MA.
